Advertisement
Sanofi Aventis
Subscribe to Sanofi Aventis

The Lead

Paralegal Says Sanofi Fired Her for Whistleblowing

December 8, 2014 8:41 am | by LINDA A. JOHNSON, AP Business Writer | News | Comments

A paralegal recently fired by French drugmaker Sanofi has filed a whistleblower lawsuit, claiming she was discharged after protesting an alleged kickback scheme to increase U.S. sales of its insulin medicines.       

FDA Approves Priftin Tablets for the Treatment of Latent Tuberculosis Infection

December 2, 2014 9:08 am | News | Comments

Sanofi announced today that following a priority review, the FDA has approved Priftin in...

Sanofi Ousts CEO Amid Pressure Over Diabetes Drug

October 29, 2014 8:08 am | by GREG KELLER, Associated Press | News | Comments

Sanofi sacked its CEO Wednesday following a board room rift over the handling of one of France's...

Sanofi Shares Plunge Due to Diabetes Drug Pricing Pressures

October 28, 2014 8:20 am | News | Comments

Sanofi saw its stock price plunge today after it reported a slide in quarterly earnings and...

View Sample

FREE Email Newsletter

Shortage of Bladder Cancer Drug Could be Tragic for Patients, Doctor Says

September 9, 2014 8:32 am | by Sheryl Ubelacker, The Canadian Press | News | Comments

The shortage of the medication — called bacillus Calmette-Guerin, or BCG — has been caused by manufacturing problems at plants operated by two different pharmaceutical companies — Merck and Sanofi Pasteur.        

Trial: Dengue Shot Offers Some Protection

July 11, 2014 8:19 am | by MARIA CHENG, AP Medical Writer | News | Comments

The most advanced vaccine for dengue only offers modest protection but could still help millions of people avoid the devastating effects of the disease known as "breakbone fever," according to a large trial.       

Analyst: Sanofi Facing Triple Threat from Eli Lilly for Diabetes Treatment Market Space

June 25, 2014 8:13 am | News | Comments

The imminent patent expiration of Sanofi’s Lantus has opened the door for Eli Lilly to increase its share of the diabetes treatment market, and the US-based company has three big weapons in its pharmaceutical arsenal, says an analyst with research and consulting firm GlobalData.

Advertisement

Sanofi and Lilly Announce Licensing Agreement for Cialis OTC

May 28, 2014 8:39 am | News | Comments

Sanofi and Eli Lilly and Company today announced an agreement to pursue regulatory approval of nonprescription Cialis (tadalafil). Cialis is currently available by prescription only worldwide for the treatment of men with erectile dysfunction (ED).

Meningococcal Vaccine Market Expected To Hit $3.76B By 2019

May 9, 2014 9:34 am | News | Comments

According to a new report published by Transparency Market Research, "Meningococcal Vaccines Market - Global Industry Analysis 2013 - 2019," the market for meningococcal vaccines was valued at USD 1.5 billion in 2012 and is expected to reach a value of USD 3.7 billion in 2019, growing at a CAGR of 14.9% from 2013 to 2019.

Former Pharma Exec Gets 16 Months in Inside-Trader Case

April 22, 2014 2:37 pm | News | Comments

A former pharmaceutical executive has been sentenced to 16 months in prison for his role in an insider trading scheme. John Lazorchak was sentenced Tuesday in federal court in Newark, N.J.           

Aastrom to Acquire Sanofi's Cell Therapy and Regenerative Medicine Business

April 21, 2014 8:41 am | News | Comments

Aastrom Biosciences announced that it has entered into a definitive agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business for a purchase price of $6.5 million.                       

Former NJ Drug Execs Sentenced in Stock Scheme

April 17, 2014 8:12 am | News | Comments

Two former pharmaceutical and medical technology firm executives have been sentenced for their involvement in an insider trading scheme.                   

Advertisement

Sanofi Earnings Soar on Lower Restructuring Costs

February 6, 2014 7:55 am | News | Comments

Sanofi said today its earnings soared in the fourth quarter as lower restructuring costs offset a hefty charge related to one of its key multiple sclerosis treatments.               

Sanofi Says Insulin U300 Met Study Goals

December 4, 2013 8:11 am | News | Comments

Sanofi said Tuesday that its insulin U300 met its primary goals in a series of clinical trials, but some results were mixed.  U300 is intended to be a longer-lasting version of Lantus that can be administered in lower doses. The company plans to file for marketing approval in the U.S. and European Union in the first half of 2014.

Whooping Cough Shot Cuts Illness, But Maybe Not Its Spread

November 26, 2013 8:08 am | by MIKE STOBBE, AP Medical Writer | News | Comments

A government study offers a new theory on why the whooping cough vaccine doesn't seem to be working as well as expected. The research suggests that while the vaccine may keep people from getting sick, it doesn't prevent them from spreading whooping cough — also known as pertussis — to others.

Sanofi Profit Slumped 21% in Q3

October 30, 2013 7:59 am | News | Comments

Sanofi said its net profit slumped by over a fifth in the third quarter as it continued to suffer the effects of overpaying for acquisitions and a painful restructuring. Sanofi SA said its net profit fell 21 percent to 1.21 billion euros ($1.66 billion) in the July to September quarter, from 1.54 billion euros a year earlier.

Study: High-Dose Flu Shot Better Protects Seniors

October 24, 2013 9:50 am | by MIKE STOBBE, AP Medical Writer | News | Comments

A new high-dose flu vaccine for seniors works better than the standard shot in that age group, according to a long-awaited study by the vaccine's manufacturer. Experts say regular flu shots tend to be only about 30 to 40 percent effective in people 65 and older, who generally have weaker immune systems.

Advertisement

Former NJ Drug Execs, Admit Roles in Stock Scheme

October 9, 2013 8:24 am | News | Comments

John Lazorchak, a former director of financial reporting at Summit-based Celgene Corp., and Mark Cupo, who held a similar position at Sanofi-Aventis, a France-based company with U.S. headquarters in Bridgewater, each pleaded guilty in federal court Monday to five counts of securities fraud.

Sanofi Re-Introduces Rolaids in the United States

September 16, 2013 8:16 am | News | Comments

Sanofi US and its consumer health business Chattem, Inc., have re-introduced Rolaids to stores across the United States. The iconic brand returns after a three-year hiatus in the marketplace and follows Chattem's acquisition of Rolaids earlier this year.

Group: China Targets Foreign Companies in Probes

September 5, 2013 8:33 am | News | Comments

The comments by officials of the European Chamber of Commerce in China follow announcements about fines imposed on dairy suppliers over pricing issues and an investigation into possibly bribery by employees of drug manufacturers GlaxoSmithKline and Sanofi.

Sanofi to Sell Pozen Cardiovascular Drugs in US

September 4, 2013 5:08 pm | by The Associated Press | News | Comments

Pozen has announced that Sanofi will handle U.S. marketing of its experimental cardiovascular drugs PA8140 and PA32540. The French drugmaker will pay Pozen $15 million upfront, and Pozen could get another $20 million in payments based on milestones before approval of the products. The companies...

Pending Research to Offer Clues for Possible H7N9 Vaccine

August 19, 2013 9:34 am | by Helen Branswell, The Canadian Press | News | Comments

Four flu vaccine manufacturers have started or will soon start clinical trials on H7N9 vaccines, with four more expected to conduct trials in the late fall or early winter, says Dr. Robin Robinson. The work will cost the U.S. government about $100 million.

China Probes Sanofi for Alleged Bribery

August 12, 2013 8:12 am | News | Comments

Chinese authorities have launched an investigation against French drugmaker Sanofi following a news report that accused the company of bribing hundreds of Chinese doctors in 2007. An unnamed whistleblower told the Guangzhou-based, state-owned 21st Century Business Herald that the French company had paid 503 doctors a total of $274,000 to prescribe Sanofi products, disguising the payments as grants for research programs.

FDA Recommends Approval of Sanofi's Nasacort® AQ Nasal Spray for OTC Use

August 1, 2013 11:22 am | News | Comments

Sanofi has announced that the Food and Drug Administration's Nonprescription Drugs Advisory Committee (NDAC) voted 10 to 6, with 2 abstentions, recommending approval of Nasacort ® AQ Nasal Spray (triamcinolone acetonide) for over-the-counter use in the U.S.

Sanofi Warns on '13 Profit as Second Quarter Earnings Slump

August 1, 2013 8:31 am | News | Comments

The Paris-based drugmaker reported Thursday that net profit shrank 62 percent to 444 million euros ($592 million) in the April to June quarter, as the loss of patent on once-popular blood-thinner Plavix compounded further massive financial charges related to the company's past mergers and acquisitions.

Sanofi Pasteur Ships First Lots of 2013-2014 Seasonal Influenza Vaccine in U.S.

July 25, 2013 9:28 am | News | Comments

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone@ (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration (FDA) for U.S. distribution and were shipped July 24

Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300

June 24, 2013 8:13 am | News | Comments

Sanofi announced today that the first Phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus® (insulin glargine [rDNA origin] injection).

NICE Draft Guidance Rejects Sanofi's Zaltrap

June 21, 2013 10:01 am | by Matthew Dennis | News | Comments

The National Institute for Health and Care Excellence issued draft guidance recommending against NHS reimbursement of Sanofi's Zaltrap (aflibercept) for treating patients with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin containing regimen. The drug was approved for this use in Europe in February.

Analysts Expect Pharma Restructuring

May 29, 2013 8:14 am | News | Comments

A group of Jefferies & Co. analysts said yesterday that drug companies are putting more emphasis on restructuring and spinning off parts of their business, and that those moves will be a critical factor in stock performance in 2013 and 2014.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading